False positivity in HER2 testing of breast cancer: Novel paths for approaching an old dilemma

Journal of Clinical Pathology

Volumn 66, Issue 11, 2013, Pages 946-950

  Nunes, Cristiana Buzelin ^a   Rocha, Rafael Malagoli ^b   Buzelin, Marcelo Araújo ^a   Balabram, Débora ^a   De Souza Foureaux, Fernanda ^a   Porto, Simone Souza ^a   Gobbi, Helenice ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DUAL COLOUR BRIGHTFIELD IN SITU HYBRIDISATION; FALSE POSITIVE RESULT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GOLD STANDARD; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY;

ANTIBODIES; BREAST CANCER; CERB 2; IMMUNOHISTOCHEMISTRY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MICE; RABBITS; RECEPTOR, ERBB-2; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84888293982     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2013-201647     Document Type: Article

References (31)

1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
2. Offersen BV, Alsner J, Ege Olsen K, et al. A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer. Acta Oncol 2008;47:618-32.
3. Ross JS. Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy. Drug News Perspect 2009;22:93-106.
4. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008;358:1409-11.
5. Hayes DF, Picard MH. Heart of darkness: the downside of trastuzumab. J Clin Oncol 2006;24:4056-8.
6. Wolff AC, Hammohd EH, Schwartz JN, et al. American society of clinical oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J Clin Oncol 2007;25:118-45.
7. Walker RA, Bartlett JMS, Dowsett M, et al. HER2 testing in the UK: further update to recommendations. J Clin Pathol 2008;61:818-24.
8. Bartlett JM, Starczynski J, Atkey N, et al. HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods. J Clin Pathol 2011;64:649-53.
9. Hardy LB, Fitzgibbons PL, Goldsmith JD, et al. Immunohistochemistry validation procedures and practices: a College of American Pathologists survey of 727 laboratories. Arch Pathol Lab Med 2013;137:19-25.
10. Dowsett M, Hanna WM, Kockx M, et al. Standardization of HER2 testing: results of an international proficiency-testing ring study. Mod Pathol 2007;20:584-91.
11. Cuadros M, Villegas R. Systematic review of HER2 breast cancer testing. Appl Immunohistochem Mol Morphol 2009;17:1-7.
12. Hammond ME. ASCO-CAP guidelines for breast predictive factor testing: an update. Appl Immunohistochem Mol Morphol 2011;19:499-500.
13. Sauter G, Lee J, Bartlett JM, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009;27:1323-33.
14. Shah S, Chen B. Testing for HER2 in Breast Cancer: a Continuing Evolution. Patholog Res Int 2010;6:2011:903202.
15. Koh YW, Lee HJ, Lee JW, et al. Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer. Mod Pathol 2011;24:794-800.
16. Schiavon BN, Jasani B, De Brot L, et al. Evaluation of Reliability of FISH Versus Brightfield Dual-probe In Situ Hybridization (BDISH) for Frontline Assessment of HER2 Status in Breast Cancer Samples in a Community Setting. Influence of Poor Tissue Preservation. Am J Surg Pathol 2012;36:1489-96.
17. Camp RL, Charaette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000;80:1943-9.
18. http://www.vassarstats.net (accessed Jan 2013).
19. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
20. Mohsin SK. HER2 testing: state of the laboratories. Arch Pathol Lab Med 2010;134:660-2.
21. Nakhleh RE, Grimm EE, Idowu MO, et al. Laboratory compliance with the American Society of Clinical Oncology/college of American Pathologists guidelines for human epidermal growth factor receptor 2 testing: a College of American Pathologists survey of 757 laboratories. Arch Pathol Lab Med 2010;134:728-34.
22. Mollerup J, Henriksen U, Müller S, et al. Dual color chromogenic in situ hybridization for determination of HER2 status in breast cancer: a large comparative study to current state of the art fluorescence in situ hybridization. BMC Clin Pathol 2012;12:3-7.
23. Perez EA, Press MF, Dueck AC, et al. Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Res Treat 2013;138:99-108.
24. Grimm EE, Schmidt RA, Swanson PE, et al. Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases. Am J Clin Pathol 2010;134:284-92.
25. Hicks DG, Kulkarni S. HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol 2008;129:263-73.
26. Rhodes A, Sarson J, Assam EE, et al. The reliability of rabbit monoclonal antibodies in the immunohistochemical assessment of estrogen receptors, progesterone receptors, and HER2 in human breast carcinomas. Am J Clin Pathol 2010;134:621-32.
27. Powell WC, Hicks DG, Prescott N, et al. A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility. Appl Immunohistochem Mol Morphol 2007;15:94-102.
28. Gouvèa AP, Milanezi F, Olson SJ, et al. Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas. Appl Immunohistochem Mol Morphol 2006;14:103-8.
29. Nunes CB, Rocha RM, Reis-Filho JS, et al. Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas. J Clin Pathol 2008;61:934-8.
30. Ricardo S, Milanezi F, Carvalho S, et al. HER2 evaluation through the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. J Clin Pathol 2007;9:1001-5.
31. van der Vegt B, de Bock GH, Bart J, et al. Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer. Mod Pathol 2009;22:879-86.